Clinical Trials

The objective of this study is to identify immune defects that compromise the immune response with age.  As humans age, vaccinations become less effective. Vaccines are only partially protective or not protective at all in older populations. Preventing or compensating these defects may improve immune responses in the elderly.

The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated. Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.

Aim 1. To examine the feasibility of a simple 5 minutes screening procedure that assesses relationship between an infant and their caregiver and the caregiver's capacity to repair and re-regulate the infants' state at 4 and 12 months WBVs (Well-Baby Visits).

Aim 2. To develop a brief and easy to implement intervention that could be applied in dyads that show signs of distress at 4 and/or 12 months vaccination appointment and examine the difference in retention rate between patients who were identified at risk at either of the appointments (at 4 or at 12 months) or at both of ...

The purpose of this study is to provide the first systematic evidence that Certified Child Life Specialists reduce pain during vaccine administration and improve caregiver visit satisfaction in the pediatric primary care setting.

A secondary aim will be to record what specific interventions are utilized by the CCLS during vaccine administration and its relation to patient-reported pain and caregiver visit satisfaction.

The purpose of this study is to determine the impact of systemic immunosuppression on sustained antibody COVID-19 concentrations in patients with inflammatory bowel disease (IBD) who received a COVID-19 vaccine.  This observational study will collect blood samples to measure sustained antibody concentrations to evaluate seroprevalence and study immunity  at 6 and 12 months after completion of vaccination.  The primary outcome of this study is to evaluate the immunogenicity of the Covid-19 vaccine in patients with IBD.

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of viral therapy in treating patients with recurrent glioblastoma multiforme.

The purpose of this study is to compare a vaccine with autologous tumor lysate loaded into yeast cell wall particles that are naturally and efficiently taken up into a patient's dendrite cells to a placebo without the autologous tumor lysate. The vaccine is formulated to treat stage III or IV resected melanoma to prevent recurrence.

The primary goal of this study is to survey pediatric nephrologists to investigate their immunization practices in children with nephrotic syndrome (NS) and to assess the parental knowledge of immunization recommendations.

The purpose of this study is to understand the role of systemic inflammation in the genesis of seizures in susceptible children by gaining a clearer understanding of the spectrum of inflammatory responses that occur in healthy children post-vaccinations.

This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

The purpose of this study is to determine if “booster” revaccination with the Janssen Ad26.CoV2.S vaccine (JNJ-78436735, aka the J&J vaccine, a viral vector vaccine) increases anti-COVID spike protein antibody levels in solid organ transplant recipients who did not form acceptable levels of anti-COVID spike protein antibody after receiving two doses of a mRNA vaccine: Pfizer-BioNTech (BNT162b2 vaccine) or Modena (mRNA-1273).